Microcap Ledger Bolt Biotherapeutics, Inc. $BOLT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Redwood City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 1,926,345 [10-Q 2026-08-11]
What the company doesAI summary of filing
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies based on its proprietary Boltbody ISAC (immune-stimulating antibody conjugate) platform technology. The company's lead program, BDC-4182, is a claudin 18.2-targeting ISAC currently in Phase 1 clinical trials for gastric and gastroesophageal junction cancer. The company does not generate product revenue and relies on research funding and milestone payments from collaboration agreements with Genmab, Toray Industries, and Innovent Biologics, as well as capital raises, to fund its development activities. Additional pipeline programs targeting CEA and PD-L1, as well as BDC-3042 targeting dectin-2, are currently on hold pending additional funding or partnerships. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $31.0K | −$14.96M | −$14.56M | $12.86M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $7.70M | −$33.38M | −$39.85M | $11.70M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $7.69M | −$63.12M | −$61.29M | $7.21M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$7.28M
- Cash runway Estimate
- ~5.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 38,273,002 | [10-Q 2024-11-12] |
| 2025-03-19 | 38,339,697 | [10-K 2025-03-24] |
| 2025-05-05 | 38,339,697 | [10-Q 2025-05-12] |
| 2025-08-07 | 1,919,441 | [10-Q 2025-08-14] |
| 2025-11-05 | 1,919,441 | [10-Q 2025-11-12] |
| 2026-03-06 | 1,921,567 | [10-K 2026-03-12] |
| 2026-05-05 | 1,921,567 | [10-Q 2026-05-12] |
| 2026-08-04 | 1,926,345 | [10-Q 2026-08-11] |
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-06] |
| 2025-01-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-18 | Yonehiro Grant | sell | 6,850 | $3.24 | [4 2026-09-21] |
| 2026-09-18 | Nemec Sarah | sell | 4,077 | $3.24 | [4 2026-09-21] |
| 2026-09-18 | Quinn William P. | sell | 9,132 | $3.24 | [4 2026-09-21] |
| 2026-09-17 | Yonehiro Grant | sell | 4,909 | $3.32 | [4 2026-09-21] |
| 2026-09-17 | Nemec Sarah | sell | 2,922 | $3.32 | [4 2026-09-21] |
| 2026-09-17 | Quinn William P. | sell | 6,545 | $3.32 | [4 2026-09-21] |
| 2026-09-16 | Yonehiro Grant | sell | 1,417 | $3.77 | [4 2026-09-21] |
| 2026-09-16 | Nemec Sarah | sell | 843 | $3.77 | [4 2026-09-21] |
| 2026-09-16 | Quinn William P. | sell | 1,889 | $3.77 | [4 2026-09-21] |
| 2026-06-05 | Nemec Sarah | buy | 509 | $3.88 | [4 2026-09-21] |
| 2026-06-05 | Quinn William P. | buy | 637 | $3.88 | [4 2026-09-21] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Material agreement entered |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-06-11 | 8-K | Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-03-12 | 10-K | Annual report |
| 2026-03-12 | 8-K | Results of operations |
| 2026-02-26 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-02-17 | 13D/A | Beneficial ownership report (5%+ holder) |
Alerts for $BOLT
Email me when Bolt Biotherapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.